EP2833871B1 - Prasugrel-containing immediate release stable oral pharmaceutical compositions - Google Patents

Prasugrel-containing immediate release stable oral pharmaceutical compositions Download PDF

Info

Publication number
EP2833871B1
EP2833871B1 EP13729057.3A EP13729057A EP2833871B1 EP 2833871 B1 EP2833871 B1 EP 2833871B1 EP 13729057 A EP13729057 A EP 13729057A EP 2833871 B1 EP2833871 B1 EP 2833871B1
Authority
EP
European Patent Office
Prior art keywords
composition
starch
prasugrel
micronized
prasugrel base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13729057.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2833871A1 (en
Inventor
András FEHÉR
Zsolt Zsigmond
Peter Tonka-Nagy
György UJFALUSSY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egis Pharmaceuticals PLC
Original Assignee
Egis Pharmaceuticals PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Pharmaceuticals PLC filed Critical Egis Pharmaceuticals PLC
Priority to PL13729057T priority Critical patent/PL2833871T3/pl
Publication of EP2833871A1 publication Critical patent/EP2833871A1/en
Application granted granted Critical
Publication of EP2833871B1 publication Critical patent/EP2833871B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to quick release prasugrel-containing pharmaceutical compositions, a process for the preparation thereof and the use of said pharmaceutical compositions together with aspirin for the prevention of atherothrombotic events of patients suffering from acute coronary syndrome, said patients having been subject to percutaneous coronary treatment.
  • compositions containing prasugrel base as active ingredient is concerned with such pharmaceutical compositions containing prasugrel base as active ingredient, a process for the preparation thereof and the combined use thereof with aspirin.
  • Prasugrel is an effective thienopyridine ADP receptor inhibitor which is irreversibly bound to the P2Y12 receptor. Prasugrel has improved therapeutical properties when compared to the previously known compounds of similar effect.
  • Effient INN name: prasugrel
  • aspirin for the prevention of atherothrombotic events of patients suffering from acute coronary syndrome said patients having been subjected to percutaneous coronary treatment such as percutaneous coronary intervention.
  • Unstable angina which is of a serious type of thoracic pain and heart attack belong to the disease group of acute coronary syndrome.
  • Percutaneous coronary surgical intervention is a type of surgery which makes the occluded, constricted coronary artery penetrable.
  • prasugrel inhibits the adenozin diphosphate induced aggregation more quickly and efficiently than clopidogrel.
  • the significance of prasugrel is increased by the fact that the use of clopidogrel failed to achieve the desired result in 2-14 % of the population of the US according to the warning of the FDA published in March 2010.
  • Prasugrel of the chemical Formula (5-/2-cyclopropyl-l-(2-fluorophenyl)-2-oxoethyl/- 4,5,6,7-tetrahydrothieno/3.2-c/-pyridine-2-yl-acetate and the preparation thereof was described first in US 5 288 726 .
  • the pharmaceutical composition was developed by Daiichi Sankyo Co. and is manufactured and marketed by Eli Lilly. In Europe the prasugrel containing pharmaceutical composition was authorized in 2009. The active ingredient of the authorized composition is prasugrel hydrochloride. Prasugrel is sensitive to moisture, elevated temperature and the oxygen content of air.
  • the hydrochloric acid salt of prasugrel was first described in EP 1 298 132 B1 . According to the patent specification, the hydrochloric acid salt is excellently absorbed after oral administration. In vivo pharmacological tests show that the bioavailability of the hydrochloric acid salt is much better than that of the prasugrel base. When administered in the same dose the platelet aggregation inhibitory effect of prasugrel hydrochloride was almost twice higher than that of the base. Polymorph form of prasugrel hydrochloride was described in WO 2011/117782 and 2010/070677 .
  • prasugrel hydrogensulfate is more stable and in pharmacological tests shows a higher bioavailability than the hydrochloride salt.
  • the publication contains examples describing the pharmaceutical compositions, however there are no data relating to the dissolution, bioavailability and stability of the compositions.
  • the inventors of WO 2011/027988 state that the solubility in distilled water of the two hydrogensulfate polymorphs developed by them is higher by one order of magnitude than that of the hydrogen chloride salts.
  • EP 2 112 155 related to the polymorph I of prasugrel hydrogen sulfate.
  • the patent application contains examples showing several pharmaceutical compositions, however neither the stability nor the pharmacokinetic characteristics thereof are disclosed.
  • EP 1 728 794 describes the preparation of the maleate salt. According to in vivo pharmacological tests the bioavailability of the maleate salt is even higher than that of the hydrochloride salt.
  • WO 2009/098142 and WO 2009/129983 are directed to the sulfonic acid salts of prasugrel. According to WO 2009/098142 , the sulfonic acid salts are more stable than the hydrochloride salt both per se and in form of pharmaceutical compositions.
  • the international publications are silent about the dissolution and bioavailability of the pharmaceutical compositions described in the examples.
  • Prasugrel base and salts are sensitive to moisture, elevated temperature and the oxygen content of the air.
  • the formulation of prasugrel either in the form of the base or a salt constitutes a challenge for the pharmacist technologist.
  • EP 2 100 607 the stability of immediate release pharmaceutical compositions is improved by coating prasugrel base or a salt thereof with a water soluble layer.
  • prasugrel base is also mentioned, in the working examples only and exclusively prasugrel hydrochloride containing compositions are disclosed.
  • EP 2100606 differs from the previous citation in that the coating layer is polyvinyl alcohol, carboxymethyl cellulose sodium or pullulan. In the examples the active ingredient is always the hydrochloride salt.
  • compositions disclosed in EP 2 100 609 contain in addition to prasugrel lactose or mannitol having a defined particle size distribution as excipient.
  • the patent application is nevertheless silent about teaching the quality of the stability and dissolution properties.
  • the examples disclose only the preparation and testing of prasugrel hydrochloride containing compositions.
  • prasugrel containing pharmaceutical compositions are stabilized by storing the tablets in air- and waterproof packaging.
  • the decomposition of prasugrel containing compositions can be reduced in air- and moisture-proof blister filled with inert gas.
  • a further problem with the formulation is that the solubility and the stability of the base is significantly lower than that of the hydrochloric acid salt. This fact is substantiated by the following Table. pH value Solubility of prasugrel base g/100 ml Solubility of prasugrel HCl g/100 ml pH 1 2.8 7.8 pH 4.5 0.0035 0.032 pH 6.8 0.001 0.007 Water 0.0009 n.d.
  • EP 2 100 610 the solubility of prasugrel is improved by adding LHPC (low-substituted hydroxypropylcellulose).
  • LHPC low-substituted hydroxypropylcellulose
  • EP 2 100 608 tablets are prepared by grinding in the presence of HPC (hydroxypropylcellulose), croscarmellose and lactose and subsequent pressing; the dissolution is considerably improved when the duration of grinding is increased.
  • HPC hydroxypropylcellulose
  • croscarmellose croscarmellose and lactose and subsequent pressing
  • WO 2011/098536 The essence of WO 2011/098536 is a process whereby micronization of prasugrel is carried out under special conditions.
  • the main feature of said process is that micronization is performed with a mixture of prasugrel and a hydrophilic polymer i.e. in the micronization step prasugrel and a hydrophilic polymer are simultaneously present.
  • hydrophilic polymers are used: hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, preferably, the sodium or calcium salt, hydroxyethyl cellulose, polyvinyl pyrrolidone, copolymers of polyvinyl pyrrolidone, preferably copolymers comprising vinyl pyrrolidone and vinyl acetate units, polyoxyethylene alkylether, polyethylene glycol, co-block polymers of ethylene oxide and propylene oxide, polymethacrylate derivatives, polyvinyl alcohol, polyvinyl derivatives and polyethylene glycol derivatives. Since the ground composition consists of two components it is not sure whether the active ingredient shows a uniform distribution in the mixture. In case of an inhomogenous mixture it can not be taken as granted that the mixture contains the predetermined nominal amount of the active ingredient and the formulation wherein the composition is used might not exhibit the required dissolution profile.
  • micronization of the active ingredient also plays a role in the improvement of the solubility of the prasugrel base.
  • Micronization belongs to the general knowledge of the person skilled in the art. In course of the preparation of the pharmaceutical composition according to the present invention we also use micronization. Our measurements carried out by means of Raman spectroscopy show that micronization was also applied in the formulation of the prasugrel hydrochloride salt i.e. in the formulation of the pharmaceutical composition of the originator. We have found that the characteristic particle size of prasugrel hydrochloride active ingredient of the originator is below 10 um.
  • the surprising recognition according to the present invention namely that in spite of the large difference between the solubility of the base and the hydrochloride salt, a pharmaceutical composition being bioequivalent to the hydrochloride salt containing composition can be prepared from the prasugrel base - said recognition is to be attributed to the auxiliary agent system of the present invention exhibiting a surprisingly strong hydrotropic effect and not to the micronization step.
  • active substances that are very difficult to process must be granulated either wet or dry methods.
  • the active substance is one of the components that are subjected to the granulation process.
  • the strongly hydrophilic auxiliary agent providing a hydrotropic environment is selected from starch and derivatives thereof can be used e.g. potato starch, wheat starch, maize starch, rice starch, tapioca starch, etc., or pre-gelatinized forms thereof, other starch derivatives, which are chemically modified or semi-synthetic starches, e.g. starch glycolates, e.g., sodium starch glycolate.
  • Type A and Type B There are two types of sodium starch glycolate according to the USP32-NF27, i.e., Type A and Type B, which differ in that sodium starch glycolate is the sodium salt of a carboxymethyl ether of starch or of a crosslinked carboxymethyl ether of starch.
  • Pregelatinized starch is a starch that has been chemically and/or mechanically processed to rupture all or part of the starch granules. Both fully and partially pregelatinized grades are commercially available. Partial pregelatinization renders the starch flowable and directly compressible. Full pregelatinization produces a coldwater soluble starch that can be used as a wet granulation binder.
  • pregelatinized starch contains 5% of free amylose, 15% of free amylopectin, and 80% unmodified starch. Normally the fully pregelatinized starch contains 20-30% amylose and the rest amylopectin, which is about the same ratio (1 : 3) as for the partially pregelatinized form.
  • prasugrel base containing solid pharmaceutical compositions which contain in addition to the prasugrel base starch or a starch derivative and at least one further auxiliary agent.
  • the composition comprises starch, namely pre-gelatinized starch and as starch derivative sodium starch glycolate.
  • starch namely pre-gelatinized starch
  • starch derivative sodium starch glycolate As further auxiliary agent, fillers, optionally adhesives, disintegrating agents and/or glidants can be used.
  • water insoluble or water soluble polymers e.g. cellulose or cellulose derivatives, sugars or sugar derivatives e.g. lactose, glucose, mannitol etc. can be used.
  • any conventional product used in pharmaceutical industry can be used e.g. crospovidone, croscarmellose or salts thereof, preferably croscarmellose sodium.
  • binders conventional products used in pharmaceutical industry can be used e.g. polyvinyl pyrrolidone or HPMC.
  • glidant preferably sodium stearyl fumarate can be used. Sodium stearyl fumarate proved to be particularly advantageous because it does not inhibit the dissolution of the active ingredient contrary to the generally used magnesium stearate.
  • colloidal silica can be used. It has been found that prasugrel base is difficult to be tableted. By adding colloidal silica, the tabletability can be surprisingly improved.
  • solid pharmaceutical compositions in tablet form According to a preferred embodiment of the present invention there are provided solid pharmaceutical compositions in tablet form.
  • coated tablets particularly coated with a water soluble coating agent.
  • tablets comprising 2-5 %, preferably 2-4 % of micronized prasugrel base, 40-80 %, preferably 60-80 % of a filler, 2-20 % preferably 5-10 % of a binder, 2-20 % preferably 5-10 % disintegrating agent, 5-20 % of starch or a starch derivative, preferably 1-3 % of a sliding agent and optionally 0.1-2 % of a glidant.
  • tablets comprising 2-5% preferably 2-4 % of micronized prasugrel base, 40-80 % preferably 60-80 % of microcrystalline cellulose, 2-20 % preferably 5-10 % of hypromellose, 2-20 % preferably 5-10 % by weight of croscarmellose sodium salt, 5-20 % of pre-gelatinized starch, 1-3 % of sodium stearyl sulfate and optionally 0.1-2 % of colloidal silicium dioxide.
  • tablets consisting of 2-5% preferably 2-4 % of micronized prasugrel base, 40-80 % preferably 60-80 % of microcrystalline cellulose, 2-20 % preferably 5-10 % of hyprormellose, 2-20 % preferably 5-10 % by weight of croscarmellose sodium salt, 5-20 % of pre-gelatinized starch, 1-3 % of sodium stearyl sulphate.
  • tablets consisting of 2-5% preferably 2-4 % of micronized prasugrel base, 40-80 % preferably 60-80 % of microcrystalline cellulose, 2-20 % preferably 5-10 % of hypromellose, 2-20 % preferably 5-10 % by weight of croscarmellose sodium salt, 5-20 % of pre-gelatinized starch, 1-3 % of sodium stearyl sulphate and 0.1-2 % of colloidal silicium dioxide.
  • the pharmaceutical compositions of the invention contain only micronized prasugrel base, and a starch or starch derivative as mandatory ingredients.
  • the composition does not contain sodium lauryl sulphate and/or magnesium stearate.
  • said embodiments also do not contain fumaric acid.
  • the composition contains sodium stearyl fumarate or stearic acid.
  • the micronized prasugrel base is not co-micronized with other ingredients, e.g., starch.
  • certain ingredients may be excluded: surfactants; mannitol, lactose and the like; pH regulators, e.g., organic acids, and also sodium lauryl sulphate and/or magnesium stearate.
  • the prasugrel base is micronized without any other ingredients, i.e., the prasugrel base is not co-micronized, e.g., with starch or cellulose, etc.
  • Co-milling can lead to unforeseen differences and inhomogeneities in the milled product mixture, leading to qualitative differences in the final milled product (due to losses of one of the ingredients during co-grinding). This may cause a quality problem then as different materials produce different losses.
  • the prasugrel base is however not micronized.
  • a process for the preparation of prasugrel base containing solid pharmaceutical compositions which comprises granulating the components of the internal phase, a part or the complete amount of the filler and the starch or starch derivative with the aqueous solution of the binder, drying the granules obtained, admixing the dry granules with the components of the external phase, the micronized prasugrel base, the remaining portion of the filler, the disintegrating agents and the glidants, homogenizing the mixture and if desired pressing into tablets or filling in capsules.
  • the tablets can be optionally coated.
  • the starch or starch derivative is dispersed/dissolved in a binder/granulating solution.
  • the starch is dissolved/dispersed in purified water together with hypromellose, for example, as exemplified in Example 2.
  • Said solution thereafter is sprayed onto fluidized microcrystalline cellulose and hypromellose, which is thereafter dried to yield granules.
  • the granules thereafter are brought together with additional ingredients, i.e., the micronized prasugrel, which has been micronized without any additional ingredients, and with either sodium stearyl fumarate or stearic acid, and other optional ingredients, for example, as provided in example 2.
  • the micronized prasugrel base particles are below 10 ⁇ m, preferably 2-6 ⁇ m, more preferably 3-5 ⁇ m. More particularly, the granulating solution containing 2-20% hypromellose in purified water is sprayed on the fluidized microcrystalline cellulose and the pregelatinized starch then the wet substance is dried, thus the obtained dried granules are mixed with a homogenized mixture of microcrystalline cellulose, Croscarmellose sodium and micronized prasugrel base and optionally colloidal silicium dioxide. The obtained mixture is homogenized, sieved and then tableted.
  • the thus obtained tablets are coated in a coating apparatus with a 10-40% mixture of film forming compound, preferably Opadry White with purified water then the obtained coated tablets are dried.
  • a coating apparatus with a 10-40% mixture of film forming compound, preferably Opadry White with purified water then the obtained coated tablets are dried.
  • 50-90% of the microcrystalline cellulose are used for the preparation of granules (Inner phase).
  • the prasugrel containing pharmaceutical composition according to the present invention is usually administered in combination with aspirin for the prevention of atherothrombolytic events of patients suffering from acute coronary syndrome who were subjected to percutant coronary intervention.
  • Acute coronary syndrome is a disease group comprising unstable angina /a serious type of thoracic pain and heart attack.
  • Percutaneous coronary intervention is a type of surgery which makes the occluded/constricted coronary artery /the vessels of the heart/ penetrable.
  • the invention relates to the following preferred aspects in any combination of said aspects.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising micronized prasugrel base, starch or starch derivative, and sodium stearyl fumarate or stearic acid.
  • the invention relates to a pharmaceutical composition wherein the starch or starch derivative is pre-gelatinized starch.
  • the invention relates to a pharmaceutical composition wherein the prasugrel base is micronized preferably without the use of any additives.
  • the invention relates to a pharmaceutical composition wherein the composition is in tablet form.
  • the invention relates to a pharmaceutical composition consisting of micronized prasugrel base, microcrystalline cellulose, hypromellose, croscarmellose sodium salt, and sodium stearyl sulphate.
  • the invention relates to a pharmaceutical composition consisting of micronized prasugrel base, microcrystalline cellulose, hypromellose, croscarmellose sodium salt, sodium stearyl sulphate and colloidal silicium dioxide.
  • the invention relates to a pharmaceutical composition wherein the composition contains no surfactants or pH regulators.
  • the invention relates to a pharmaceutical composition wherein the composition contains no mannitol, lactose, organic acids, magnesium stearate, HCL, hydrogen sulphate, sodium lauryl sulphate, xylitol or fumaric acid.
  • the invention relates to a pharmaceutical composition wherein the starch is not sodium starch glycolate.
  • the invention relates to a pharmaceutical composition wherein the composition is substantially free of a prasugrel salt.
  • the invention relates to a pharmaceutical composition wherein the starch comprise 5%-20% by weight of the total composition.
  • the invention relates to a pharmaceutical composition wherein the micronized prasugrel base comprises 2%-5% by weight of the total composition.
  • the invention relates to a pharmaceutical composition wherein the sodium stearyl fumarate or stearic acid comprises 1%-3% by weight of the total composition.
  • the invention relates to a pharmaceutical composition wherein the size of the micronized prasugrel base particles are below 10 ⁇ m, preferably 2-6 ⁇ m, more preferably 3-5 ⁇ m
  • the invention relates to a pharmaceutical composition consisting essentially of:
  • the invention relates to a method of treating atherothrombotic events of patients suffering from acute coronary syndrome in which patients were subjected to percutaneous coronary intervention, said method comprising:
  • the invention relates to a pharmaceutical composition prepared by a process comprising:
  • the invention relates to a pharmaceutical composition prepared by a process comprising:
  • the invention relates to a pharmaceutical composition wherein the resulting mixture, e.g., from aspect 18, is pressed into tablets.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising:
  • the invention relates to a pharmaceutical composition wherein the composition of aspect 21 is in tablet form.
  • Tablets comprising prasugrel
  • composition of Opadry II. 33G28523 white Hypromellose 40.00 % Titanium dioxide 25.00 % Lactose monohydrate 21.00 % Macrogol 3350 8.00 % Glycerol triacetate 6.00 %
  • the granulating solution is prepared.
  • the hypromellose is dissolved in the purified water under stirring.
  • the hypromellose solution is sprayed onto the fluidized microcrystalline cellulose and the Starch 1500.
  • the wet substance is then dried /drying loss 2-2.2 %, measured at 90°C after 10 minutes.
  • Addition rate of the granulating solution about 50 g/minute
  • Temperature of the introduced air 60°C during granulation, 75°C during drying.
  • Pruv sodium stearyl fumarate
  • Tableting is carried out on a Korsch XM 12 rotating tableting machine.
  • the Opadry II 33G28523 White is added in small portions under stirring to the purified water.
  • the system is stirred for 45 minutes whereupon it is sieved on a 0.5 mm sieve.
  • 500 g of the tablet core are coated in a Lodige LHC 30 type film coating apparatus.
  • the weight gain of the cores is 6 mg/tablet core /for 5 mg tablets/ and 12 mg/tablet core /for 10 mg tablets/, respectively.
  • Tablets comprising prasugrel
  • composition of Opadry II. 33G28523 white Hypromellose 40.00 % Titanium dioxide 25.00 % Lactose monohydrate 21.00 % Macrogol 3350 8.00 % Glycerol triacetate 6.00 %
  • the granulating solution is prepared.
  • the hypromellose and Starch 1500 are dispersed in the purified water under stirring.
  • the granulation fluid is sprayed on the fluidized microcrystalline cellulose and the hypromellose.
  • the wet substance is then dried /drying loss 2-2.2 %, measured at 90°C after 10 minutes.
  • Addition rate of the granulating solution about 50 g/minute
  • Temperature of the introduced air 60°C during granulation, 75°C during drying. From the granules prepared, batches of 500 g each are used for the preparation of the next homogenized mixture.
  • Pruv sodium stearyl fumarate
  • Tableting is carried out on a Korsch XM 12 rotating tableting machine.
  • the Opadry II 33G28523 White is added in small portions under stirring to the purified water.
  • the system is stirred for 45 minutes whereupon it is sieved on a 0.5 mm sieve.
  • 500 g of the tablet core are coated in a Lodige LHC 30 type film coating apparatus.
  • the weight gain of the cores is 6 mg/tablet core /for 5 mg tablets/ and 12 mg/tablet core /for 10 mg tablets/, respectively.
  • composition of the tablet core is Composition of the tablet core
  • Bioequivalence of Prasugrel 10 mg tablets of Example 1 and EffientTM 10 mg tablets (Eli Lilly and Company, USA) following administration of 30 mg dose was investigated in a single dose, 2-period, 2-treatment, 2-sequence crossover study in healthy subjects taking lansoprazole for at least 1 week under fasting condition.
  • Thirty male non smoker healthy volunteers were randomly assigned to a treatment sequence and received two separate single 30 mg (3x10 mg tablets) dose administration of investigational medications following 7-day lansoprazole pretreatment according to a randomized schedule. Subjects fasted overnight for at least 10 hours prior to prasugrel administration.
  • Bioequivalence was based on a parametric ANOVA model and two-sided 90% confidence interval of the ratio of geometric means for the In-transformed C max , AUC T and AUC ⁇ . Bioequivalence was concluded if the 90% geometric confidence intervals of the test/reference ratio of least-squares means for In-transformed C max , AUC T , and AUC ⁇ were within the acceptable range of 80.00% to 125.00% for the main inactive metabolite (R-95913) of prasugrel. Statistical analysis of the active metabolite of prasugrel (R-138727) was performed for supportive purpose.
  • Prasugrel formulation of Example 1 containing prasugrel base and EffientTM formulation was bioequivalent under fed condition based on both the main inactive metabolite (R-95913) and the main active metabolite (R-138727).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP13729057.3A 2012-04-02 2013-04-02 Prasugrel-containing immediate release stable oral pharmaceutical compositions Active EP2833871B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL13729057T PL2833871T3 (pl) 2012-04-02 2013-04-02 Zawierająca prasugrel stabilna doustna kompozycja farmaceutyczna o natychmiastowym uwalnianiu

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/437,087 US8603537B2 (en) 2012-04-02 2012-04-02 Prasugrel containing quickly released stable oral pharmaceutical compositions
PCT/HU2013/000031 WO2013150322A1 (en) 2012-04-02 2013-04-02 Prasugrel-containing immediate release stable oral pharmaceutical compositions

Publications (2)

Publication Number Publication Date
EP2833871A1 EP2833871A1 (en) 2015-02-11
EP2833871B1 true EP2833871B1 (en) 2017-07-19

Family

ID=48626468

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13729057.3A Active EP2833871B1 (en) 2012-04-02 2013-04-02 Prasugrel-containing immediate release stable oral pharmaceutical compositions

Country Status (18)

Country Link
US (1) US8603537B2 (zh)
EP (1) EP2833871B1 (zh)
KR (1) KR20150003726A (zh)
CN (1) CN103717209B (zh)
AU (1) AU2013245425A1 (zh)
CA (1) CA2869281A1 (zh)
CO (1) CO7111279A2 (zh)
EA (1) EA028329B1 (zh)
HK (1) HK1198466A1 (zh)
HU (1) HUE034564T2 (zh)
IL (1) IL234931A0 (zh)
MX (1) MX2014011033A (zh)
NZ (1) NZ631426A (zh)
PE (1) PE20142460A1 (zh)
PH (1) PH12014502221A1 (zh)
PL (1) PL2833871T3 (zh)
UA (1) UA116204C2 (zh)
WO (1) WO2013150322A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360159A1 (de) 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
CN103610674B (zh) * 2013-12-09 2015-01-07 海南灵康制药有限公司 一种含微粉化的普拉格雷的固体制剂
WO2016122421A1 (en) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Stable pharmaceutical compositions containing prasugrel base
EP3158993A1 (en) * 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Process for preparing a tablet comprising prasugrel or pharmaceutically acceptable salt thereof
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
AU2001267916B2 (en) 2000-07-06 2004-09-09 Daiichi Sankyo Company, Limited Hydropyridine derivative acid addition salts
UA79498C2 (en) 2002-09-05 2007-06-25 Kissei Pharmaceutical Intermediates for preparation of phenoxy-acetic derivates and processes of their preparation
US20050195079A1 (en) 2004-03-08 2005-09-08 David Cohen Emergency situation detector
TWI318571B (en) 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
WO2008072534A1 (ja) 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited マンニトール又は乳糖を含有する固形製剤
CA2672154C (en) 2006-12-07 2014-11-18 Daiichi Sankyo Company, Limited Pharmaceutical composition having improved storage stability
US20110201814A1 (en) 2006-12-07 2011-08-18 Daiichi Sankyo Company Limited Method for producing solid preparation
KR101665705B1 (ko) 2006-12-07 2016-10-12 다이이찌 산쿄 가부시키가이샤 안정성이 개선된 필름 코팅 제제
BRPI0719393B8 (pt) 2006-12-07 2021-05-25 Daiichi Sankyo Co Ltd composição farmacêutica
WO2008073759A2 (en) 2006-12-07 2008-06-19 Eli Lilly And Company An article comprising prasugrel
CN101177430A (zh) 2007-12-11 2008-05-14 鲁南制药集团股份有限公司 氢化吡啶衍生物及其盐的制备方法
EP2257556A1 (en) 2008-02-06 2010-12-08 Helm AG Prasugrel salts with improved properties
WO2009129983A1 (en) 2008-04-21 2009-10-29 Ratiopharm Gmbh Acid addition salts of prasugrel and pharmaceutical compositions comprising the same
ATE482961T1 (de) 2008-04-25 2010-10-15 Sandoz Ag Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung
US20090281136A1 (en) * 2008-05-08 2009-11-12 Sandeep Mhetre Prasugrel pharmaceutical formulations
WO2010070677A2 (en) 2008-12-15 2010-06-24 Glenmark Generics Limited A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof
WO2010094471A1 (en) 2009-02-17 2010-08-26 Krka, D. D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
JP5501438B2 (ja) 2009-03-31 2014-05-21 上海医薬工業研究院 プラスグレル臭化水素酸塩の結晶
GB2469883A (en) 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
WO2011004392A1 (en) 2009-07-06 2011-01-13 Glenmark Generics Limited Crystalline form of prasugrel hydrobromide, preparation and application thereof
KR20110024057A (ko) 2009-09-01 2011-03-09 한미홀딩스 주식회사 신규한 프라수그렐 황산수소염의 결정다형
WO2011036533A1 (en) * 2009-09-23 2011-03-31 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising prasugrel and triflusal
DE102009052887B4 (de) 2009-11-13 2016-09-15 Otto Bock Healthcare Products Gmbh Verfahren zur Steuerung eines orthetischen oder prothetischen Gelenkes einer unteren Extremität
CZ2009762A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
EP2360159A1 (de) 2010-02-11 2011-08-24 Ratiopharm GmbH Prasugrel in mikronisierter, kristalliner Form und pharmazeutische Zusammensetzung davon
EP2528924A1 (en) 2010-03-23 2012-12-05 Alembic Pharmaceuticals Limited A process for the preparation of prasugrel hcl salt
CN101804042A (zh) * 2010-04-16 2010-08-18 山东新华制药股份有限公司 普拉格雷片剂的制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
IL234931A0 (en) 2014-12-31
EA028329B1 (ru) 2017-11-30
WO2013150322A1 (en) 2013-10-10
EA201491831A1 (ru) 2015-01-30
EP2833871A1 (en) 2015-02-11
AU2013245425A1 (en) 2014-10-23
PE20142460A1 (es) 2015-02-05
CN103717209A (zh) 2014-04-09
KR20150003726A (ko) 2015-01-09
CO7111279A2 (es) 2014-11-10
MX2014011033A (es) 2015-09-23
HUE034564T2 (en) 2018-02-28
PH12014502221A1 (en) 2015-01-12
NZ631426A (en) 2015-09-25
UA116204C2 (uk) 2018-02-26
US20130259904A1 (en) 2013-10-03
CA2869281A1 (en) 2013-10-10
HK1198466A1 (zh) 2015-05-08
CN103717209B (zh) 2017-07-18
PL2833871T3 (pl) 2017-12-29
US8603537B2 (en) 2013-12-10

Similar Documents

Publication Publication Date Title
EP2448561B1 (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
EP3437646A1 (en) Oral preparation having exceptional elutability
EP2833871B1 (en) Prasugrel-containing immediate release stable oral pharmaceutical compositions
MXPA05006513A (es) Farmaco solido para uso oral.
EP3744320A1 (en) Pharmaceutical tablet composition comprising edoxaban
EP2514422B1 (en) Elution stabilized teneligliptin preparation
EP1976522B1 (en) Pharmaceutical composition containing montelukast
WO2020175897A1 (ko) 미라베그론 또는 그의 약제학적으로 허용되는 염을 함유한 방출조절 제제
EP2538924B1 (en) Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation
EP4032529A1 (en) Sorafenib pharmaceutical composition having high bioavailability and application
EP3437645B1 (en) Film-coated tablet having high chemical stability of active ingredient
KR20180036633A (ko) 용출율이 향상된 라록시펜, 및 비타민 d 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
EP3219309A1 (en) Fixed dosed pharmaceutical composition comprising amlodipine, candesartan cilexetil and hydrochlorothiazide for the treatment of hypertension
EP3505158A1 (en) Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
HU231052B1 (hu) Bisoprololt és ramiprilt tartalmazó stabil kombinációs gyógyszerkészítmény
KR102286497B1 (ko) 다양한 용량의 레날리도마이드의 경구용 정제 조성물
EP2903593B1 (en) Tablet containing composite with cyclodextrin
KR101534606B1 (ko) 사포그릴레이트의 안정화된 지속 방출 제제
EP2471519B1 (en) Controlled release formulation of carvedilol
US20030180354A1 (en) Amlodipine maleate formulations
EP4302832A1 (en) Palbociclib formulation containing glucono delta lactone
EP3079672B1 (en) Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline
EP4302755A1 (en) Palbociclib formulation containing an amino acid
EP4282415A1 (en) A stable tablet composition of axitinib
EP4238555A2 (en) Immediate release fixed-dose combination of memantine and donepezil

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141002

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170113

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

INTC Intention to grant announced (deleted)
GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

INTG Intention to grant announced

Effective date: 20170613

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 909706

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170815

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013023730

Country of ref document: DE

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170719

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 909706

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171019

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171020

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171119

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E034564

Country of ref document: HU

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 25605

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013023730

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

26N No opposition filed

Effective date: 20180420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180430

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180402

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170719

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20230307

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230412

Year of fee payment: 11

Ref country code: DE

Payment date: 20230419

Year of fee payment: 11

Ref country code: BG

Payment date: 20230425

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20230310

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230417

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20240305

Year of fee payment: 12

Ref country code: CZ

Payment date: 20240305

Year of fee payment: 12

Ref country code: SK

Payment date: 20240307

Year of fee payment: 12